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Abstract
Background
Arteriovenous fistulas (AVF) for haemodialysis often experience early thrombosis and matu-
ration failure requiring intervention and/or central venous catheter (CVC) placement. This
secondary and exploratory analysis of the FAVOURED study determined whether omega-3
fatty acids (fish oils) or aspirin affected AVF usability, intervention rates and CVC
requirements.
Methods
In 567 adult participants planned for AVF creation, all were randomised to fish oil (4g/d) or
placebo, and 406 to aspirin (100mg/d) or placebo, starting one day pre-surgery and contin-
ued for three months. Outcomes evaluated within 12 months included AVF intervention
rates, CVC exposure, late dialysis suitability failure, and times to primary patency loss,
abandonment and successful cannulation.
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Results
Final analyses included 536 participants randomised to fish oil or placebo (mean age 55
years, 64% male, 45% diabetic) and 388 randomised to aspirin or placebo. Compared with
placebo, fish oil reduced intervention rates (0.82 vs 1.14/1000 patient-days, incidence rate
ratio [IRR] 0.72, 95% confidence interval [CI] 0.54–0.97), particularly interventions for acute
thrombosis (0.09 vs 0.17/1000 patient-days, IRR 0.53, 95% CI 0.34–0.84). Aspirin signifi-
cantly reduced rescue intervention rates (IRR 0.45, 95% CI 0.27–0.78). Neither agent signif-
icantly affected CVC exposure, late dialysis suitability failure or time to primary patency loss,
AVF abandonment or successful cannulation.
Conclusion
Although fish oil and low-dose aspirin given for 3 months reduced intervention rates in newly
created AVF, they had no significant effects on CVC exposure, AVF usability and time to pri-
mary patency loss or access abandonment. Reduction in access interventions benefits
patients, reduces costs and warrants further study.
Introduction
A functioning vascular access is essential for patients requiring haemodialysis (HD). A native
arteriovenous fistula (AVF) has the best long-term outcomes although this advantage is fre-
quently limited by early thrombosis, maturation failure, the need for access interventions and/
or placement of a central venous catheter (CVC)[1,2]. Vascular access interventions are bur-
densome for patients and incur significant health care costs[3]. Patients and health profession-
als consider the need for interventions to maintain the use of a vascular access for HD the
most important adverse outcome of a vascular access[4], yet treatments to reduce intervention
rates and to increase the usability of AVF have not been a major focus of randomised trials in
patients requiring HD[5]. The inhibitory effects of omega-3 polyunsaturated fatty acids (fish
oils) on platelet aggregation[6,7], inflammation[8,9], and neointimal hyperplasia[10], and of
aspirin on platelet inhibition could be beneficial in reducing the need for interventions for
acute thrombosis and maturation-enhancing procedures. Fish oil supplementation has been
shown to reduce intervention and thrombosis rates in arteriovenous grafts[11] but has not pre-
viously been studied in AVF.
The omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Dis-
ease (FAVOURED) trial found that neither fish oil nor aspirin reduced the primary outcome
‘AVF failure’, a binary composite outcome comprising AVF thrombosis and/or AVF abandon-
ment and/or cannulation failure assessed at 12 months following AVF creation[12]. The cur-
rent analysis of secondary and exploratory outcomes of the FAVOURED trial aimed to
determine whether fish oil or low-dose aspirin could reduce the need for access interventions
and CVC exposure and/or increase the usability of newly created AVF for HD.
Materials and methods
Design and population
The design and results of the main outcomes of the FAVOURED study have been published
[12–16] and the study protocol and statistical analysis plan are provided in Supporting
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Information S1 and S2 Files, respectively. FAVOURED was a prospective, double-blind, ran-
domised controlled trial conducted in Australia, New Zealand, the United Kingdom and
Malaysia involving 567 adults with stage 4 or 5 chronic kidney disease who were receiving or
expected to receive HD within 12 months and scheduled for AVF surgery. The original study
protocol underwent two amendments after study initiation[14]: First, the primary outcome of
“early thrombosis” within 12 weeks of AVF creation was broadened to the clinically important
outcome of “AVF access failure”, a composite of thrombosis and/or AVF abandonment and/
or cannulation failure at 12 months. Second, the exclusion criteria of aspirin use were removed
to allow participants on medically indicated aspirin to be randomised to fish oil or matching
placebo and to continue using an open-label aspirin. Participants were randomly allocated in a
1:1 ratio to receive either fish oil (4g/d, 46% eicosapentaenoic acid and 38% docosahexaenoic
acid) or matching placebo (olive oil). A subset of 406 participants either not taking aspirin or
able to cease it prior to enrolment were further randomised in a 1:1 ratio to receive 100mg of
oral aspirin daily or matching placebo. Treatment commenced one day prior to surgery and
continued for 12 weeks. Participants were randomised via a central, web-based system (Flexe-
trials) using an adaptive minimisation algorithm with study site and planned AVF location
(upper versus lower arm) as minimisation variables. Participants and care providers, labora-
tory staff and members of the study team were blinded to treatment allocation. Ethics approval
for the Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal
Disease (FAVOURED) trial was obtained from local Human Research Ethics Committees
(HREC) in all participating centres prior to study initiation and participant enrolment.
Approving HRECs included: Australia—Austin Health HREC, Cairns & Hinterland Health
Service District HREC, Ethics Review Committee (RPAH Zone), South Metropolitan Area
Health Service HREC, Barwon Health HREC, Gold Coast Health Service District HREC,
Greenslopes Private Hospital Ethics Committee, Tasmanian Health and Medical HREC,
Southern Health HREC C, Metro South HREC, Royal Adelaide Hospital Research Ethics
Committee, Melbourne Health HREC, Royal Perth Hospital HREC, Sir Charles Gairdner Hos-
pital HREC, Sydney Adventist Hospital HREC, Sir Charles Gairdner Hospital HREC, Sydney
Adventist Hospital HREC, The Alfred Ethics Committee, Australian Capital Territory Health
HREC, Ethics of Health Research Committee (TQEH & LMH), Darling downs–West Moreton
(Toowoomba & Darling Downs) Health Service District HREC, Townsville Health Service
District HREC, The University of Queensland Medical Research Ethics Committee; New Zea-
land—Multi-region Ethics Committee; Malaysia—Ministry of Health Malaysia Medical
Research & Ethics Committee; and the United Kingdom—National Research Ethics Service
Nottingham Research Ethics Committee. The study was performed in accordance with the
Declaration of Helsinki and written consent was obtained from all participants. The study was
terminated early because of slower than anticipated recruitment, funding issues and lack of
ongoing availability of trial medications. Two interim efficacy analyses using the Haybittle-
Peto rule were planned after one-third and two-thirds of recruited patients with at least 12
months follow-up, but only the first interim analysis was conducted due to early trial cessation.
FAVOURED was registered with the Australia & New Zealand Clinical Trials Register
(ACTRN12607000569404).
Outcomes
Pre-specified secondary[12] and exploratory outcomes included the number and type of inter-
ventions from AVF creation to 12 months, and the time to the first intervention. Interventions
comprised rescue procedures designed to restore patency of the AVF (medical thrombolysis or
surgical thrombectomy) and non-rescue procedures (surgical or radiological revision or
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dilation of the AVF from or proximal to the anastomosis to the ipsilateral central vein, dilation
of central venous stenosis, ligation of tributaries, superficialisation of the AVF, ligation of the
AVF or salvage by distal reconstruction and interval ligation due to distal ischemia). Additional
secondary outcomes encompassed the time to first successful cannulation (the time between
surgery and first of three consecutive successful cannulations), time to primary patency loss
(first thrombosis or need for rescue intervention), time to permanent AVF abandonment, time
to abandonment or primary patency loss, and CVC exposure for HD (binary and count [dura-
tion in situ] outcome). Exploratory analyses included the binary outcomes of primary patency
loss within the first 12 months and late dialysis suitability failure[17] (inability to cannulate the
study AVF for at least 8 out of 12 consecutive HD sessions or access abandonment by 6 months
post-surgery). S1 Table provides a summary of the outcomes and definitions.
Statistical analysis
Continuous variables were expressed as mean [± standard deviation] or median [interquartile
range] depending on the distribution and categorical variables as numbers and percentages.
Pearson’s Chi-square test or Fisher’s exact test were used to compare categorical data as appro-
priate. Treatment effects for binary outcomes were determined by log-binomial regression and
expressed as relative risks (RR) and 95% confidence interval (CI). Incidence rate ratios from
Poisson regression were used for treatment comparisons on count outcomes. Cox propor-
tional sub-distribution hazards models were used to compare treatment effects on time to first
intervention, first successful cannulation and AVF abandonment treating death and transplan-
tation as competing events. The proportional hazards assumption was tested by adding an
interaction between treatment and time to each model. As there were few competing risks
(<1% to 2.4%), survival results were displayed as Kaplan-Meier curves with 95% CI and com-
peting events censored. All outcome comparisons of fish oil with placebo were adjusted for dif-
ferences in aspirin use (randomised to aspirin, randomised to placebo aspirin, open-label
aspirin). The robustness of the fish oil effect was assessed by additional analyses that adjusted
for pre-specified baseline characteristics (planned AVF site, diabetes mellitus, age, cardiovas-
cular comorbidities, and renal replacement therapy at baseline) and study region (Australia
and New Zealand, Malaysia and the United Kingdom). The same statistical methods were
used for the comparison of aspirin with matching placebo. A two-sided p-value less than 0.05
was considered statistically significant. Statistical analyses were performed using SAS version
9.4 (SAS Institute).
Results
The FAVOURED study randomised 567 participants to fish oil or placebo from August 21,
2008 to February 28, 2014, of which 536 were included in the final analysis[12]Fig 1. Table 1
shows the baseline characteristics of the 536 participants; 31 participants were excluded
because they either died prior to being assessed on any outcome (n = 5 in each of the fish oil
and placebo groups) or did not have an AVF created (n = 9 randomised to fish oil, n = 12 ran-
domised to placebo)[12]. Participants had a mean age of 55 years and 64% were male. Baseline
characteristics were generally well balanced although more participants treated with fish oil
compared to placebo were diabetic (48% versus 43%) or smokers (53% versus 48%). At study
initiation, 49% were on dialysis with 84% dialysing through a CVC. At study end, 83% received
dialysis with 61% using the study AVF (167 [62%] randomised to fish oil, 159 [60%] rando-
mised to placebo).
Of the 406 participants not taking aspirin or able to cease it prior to enrolment, 203 were
randomised to aspirin and 203 to matching placebo[12] of which 388 (194 in each group) were
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included in the analysis (S1 Fig). The remaining 18 participants were excluded because they
either did not undergo AVF creation (n = 5 randomised to aspirin, n = 8 randomised to pla-
cebo) or died before they could be assessed on any outcome (n = 4 randomised to aspirin,
n = 1 randomised to placebo). As outlined in Table 1, this subset of 388 participants had a
lower prevalence of cardiovascular disease (7% randomised to aspirin, 5% randomised to
Fig 1. CONSORT participant flow diagram.
https://doi.org/10.1371/journal.pone.0213274.g001
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Table 1. Patient demographics and baseline characteristics for fish oil versus placebo and separately for the subset of aspirin versus placebo.
Characteristics Fish oil (n = 270) Placebo (n = 266) Aspirin (n = 194) Placebo (n = 194)
Age, (years, mean ± SD) 54.2 ± 14.1 55.9 ± 14.7 52.4 ± 14.6 54.2 ± 14.9
Male, n (%) 171 (63) 171 (64) 120 (62) 126 (65)
Country, n (%)
Australia and New Zealand 192 (71) 191 (72) 150 (74) 147 (72)
Malaysia 75 (28) 69 (26) 53 (26) 53 (26)
United Kingdom 3 (1) 6 (2) 0 3 (2)
Ethnicity, n (%)
Asian 88 (33) 81 (31) 66 (34) 56 (29)
White 139 (52) 150 (56) 102 (53) 117 (60)
Indigenousa 34 (13) 25 (9) 22 (11) 15 (8)
Other 9 (3) 10 (4) 4 (2) 6 (3)
Body mass index, (kg/m2; mean ± SD) 28.8 ± 7.4 28.3 ± 7.0 27.7 ± 6.6 28.4 ± 7.7
Blood pressure, (mm Hg; mean ± SD)
Systolic 146 ± 23 146 ± 23 145 ± 22 146 ± 24
Diastolic 82 ± 14 81 ± 13 81 ± 13 83 ± 14
Comorbid conditions
Diabetes mellitus, n (%) 130 (48) 113 (43) 79 (41) 70 (36)
Cardiovascular disease, n (%) 39 (14) 40 (15) 14 (7) 10 (5)
Hypertension, n (%) 234 (87) 241 (91) 174 (90) 172 (89)
Current or prior smoking, n (%) 144 (53) 128 (48) 92 (47) 93 (48)
Medications
Aspirin, n (%) 71 (26) 72 (27) NA NA
Statin, n (%) 143 (53) 132 (50) 79 (41) 87 (45)
ESA, n (%) 119 (44) 134 (50) 99 (51) 90 (46)
Beta-blocker, n (%) 123 (46) 124 (47) 91 (47) 77 (40)
ARB/ACEI, n (%) 108 (40) 116 (44) 85 (44) 80 (41)
CCB, n (%) 150 (56) 149 (56) 113 (58) 103 (53)
Planned study AVF location, n (%)b
Upper arm 104 (39) 103 (39) 84 (41) 82 (40)
Forearm 166 (62) 163 (61) 119 (59) 121 (60)
Renal replacement therapy at time of AVF creation, n (%)
Peritoneal dialysis 14 (5) 19 (7) 16 (8) 10 (5)
Haemodialysis 115 (43) 111 (42) 79 (41) 88 (45)
Not currently receiving dialysis 141 (52) 136 (51) 99 (51) 96 (50)
Principal access currently in use for participants receiving dialysis, n (%)
AVF 5 (4) 2 (2) 2 (2) 1 (1)
AVG 0 1 (1) 0 0
CVC (cuffed and non-cuffed) 110 (85) 108 (83) 77 (81) 87 (89)
Peritoneal dialysis catheter 14 (11) 19 (15) 16 (17) 10 (10)
Dialysis duration (months; median [IQR])c 3.8 [1.8, 18.2] 4.2 [1.9, 16.1] 4.6 (2.0, 16.3) 4.0 (1.7, 15.1)
aAboriginal, Torres Strait Islanders, Maori and Pacific Islanders
bActual AVF location upper arm versus forearm: fish oil n = 110 (41%) versus n = 160 (59%); placebo n = 107 (40%) versus n = 159 (60%); aspirin n = 79 (41%) versus
n = 115 (59%); placebo n = 79 (41%) versus n = 115 (59%).
cFor pre-dialysis participants only (fish oil n = 141 and placebo n = 136; aspirin n = 99 and placebo n = 96)
Abbreviations: ACEI–angiotensin-converting enzyme inhibitor; AVF–arteriovenous fistula; ARB–angiotensin receptor blocker; CCB–calcium channel blocker; CVC–
Central venous catheter; eGFR–estimated glomerular filtration rate; ESAs–erythropoietin stimulating agents; IQR–interquartile range; N/A–not applicable; SD–
standard deviation.
https://doi.org/10.1371/journal.pone.0213274.t001
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Fig 2. Number of rescue- and non-rescue interventions by time period for fish oil versus placebo (A) and aspirin versus
placebo (B). �p = 0.009 (Fisher’s Exact Test) for comparison of rescue intervention during first 3 months (active treatment phase)
and beyond 3 months.
https://doi.org/10.1371/journal.pone.0213274.g002
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placebo) compared to the full set of 536 participants randomised to fish oil (14%) or matching
placebo (15%).
AVF interventions
Fig 2 and S2 Table present the frequency and type of AVF interventions by treatment arms for fish
oil versus placebo (A) and aspirin versus placebo (B). Overall, 22% of participants receiving fish oil
supplementation required at least one AVF intervention compared to 27% treated with placebo
(S2 Table). Of those, 17% treated with fish oil and 28% treated with placebo required more than
one intervention. The majority of interventions occurred within the first 6 months of AVF crea-
tion (Fig 2). Neither fish oil nor aspirin reduced the risk of needing at least one rescue- or non-res-
cue intervention compared to their matching placebo. Similarly, the time to first intervention was
not significantly reduced by fish oil or aspirin (Fig 3A and 3B; HR 0.85, 95% CI 0.57, 1.26, p = 0.41
for fish oil versus placebo; HR 0.81, 95% CI 0.51, 1.29, p = 0.38 for aspirin versus placebo). As
shown in Fig 4A, intervention rates were significantly reduced by fish oil compared to placebo,
driven by a significant reduction in rescue procedures (IRR 0.53 95% CI 0.34, 0.84, p = 0.005).
The effect size remained similar when adjusting for pre-specified baseline characteristics and geo-
graphical regions. Of note, there was a significant reduction in the number of rescue interventions
with fish oil during the active treatment period, i.e. the first 3 months, compared with placebo
(p = 0.009) (Fig 2A). Similarly, the rate of rescue interventions was reduced in the participants
treated with low-dose aspirin compared to matching placebo (Fig 4B). The fish oil by aspirin inter-
action test was not statistically significant for rescue or non-rescue interventions (p = 0.12).
Primary patency loss and AVF abandonment
The proportion of participants with primary patency loss within 12 months of their AVF crea-
tion was not significantly reduced by fish oil (70/270 [26%] participants) compared to placebo
(81/266 [31%]; RR 0.85, 95% CI 0.65, 1.12, p = 0.25). Similarly, the time to primary patency
loss was not significantly improved in the fish oil treated group compared to placebo (HR 0.81,
95% CI 0.51, 1.29, p = 0.38), as shown in Fig 5A. In participants treated with aspirin or match-
ing placebo, primary patency loss occurred in 27% of participants in both treatment arms and
the time to primary patency loss was similar for aspirin and placebo treated participants (Fig
5B; HR 1.01, 95% CI 0.69, 1.47, p = 0.98). Fig 6 shows that neither fish oil (6A) nor aspirin (6B)
led to a significant prolongation in the time to AVF abandonment. Similarly, time to either
primary patency loss or AVF abandonment was not altered by fish oil (HR 0.92, 95% CI 0.69–
1.21, p = 0.53) or aspirin (HR 1.01, 95% CI 0.73–1.42, p = 0.94).
CVC requirements
Half of the participants required at least one CVC within the first 12 months of AVF creation
and this was not reduced by fish oil (RR 1.00, 95% CI 0.84, 1.19, p = 0.97) or aspirin (RR 0.93,
95% CI 0.76, 1.14, p = 0.48) compared to their matching placebos. The median number of days
CVCs stayed in situ was comparable in the fish oil and placebo groups (101 days, IQR 56–175
versus 101 days, IQR 57–176, IRR 0.96, 95% CI 0.76, 1.21, p = 0.73). No significant difference
in CVC exposure time was found between participants treated with aspirin or matching pla-
cebo (103 days, IQR 63–154 versus 87 days, IQR 54–157, IRR 0.91 95% CI 0.69, 1.19, p = 0.48).
Fig 3. Time to first AVF intervention for fish oil versus placebo (A) and aspirin versus placebo (B). Kaplan-Meier curve
for active therapy (solid line with 95% confidence interval in light gray) and matching placebo (dashed line with 95%
confidence interval in dark gray).
https://doi.org/10.1371/journal.pone.0213274.g003
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AVF usability
Of the 356 participants who required HD within 6 months of AVF surgery, 36% on fish oil
and 34% on placebo were unable to use the AVF for HD (RR 1.05, 95% CI 0.79, 1.39, p = 0.73).
Aspirin was similarly ineffective in reducing late dialysis suitability failure compared to pla-
cebo (47/135 [35%] versus 38/124 [31%], RR 1.14, 95% CI 0.80, 1.61, p = 0.48). By 12 months
following AVF surgery, 444 participants received dialysis and 74% of participants in the fish
oil group and 73% of those in the placebo group had three consecutive successful cannulations
of their AVF. Neither fish oil (HR 1.03, 95% CI 0.83–1.28, p = 0.77) nor aspirin (HR 0.89, 95%
CI 0.69–1.15, p = 0.37) reduced the time to first successful cannulation of the study AVF (Fig
7A and 7B).
Discussion
Secondary and exploratory outcome analyses of the FAVOURED trial showed that a quarter
of participants required at least one AVF intervention within the first year of AVF creation,
almost 30% experienced primary patency loss and 50% required at least one CVC. Three
months of fish oil supplementation reduced the rate of AVF interventions, principally driven
by a 47% relative reduction in rescue procedures for acute thrombosis. Similarly, low-dose
aspirin reduced the incidence of rescue interventions by 55%. However, neither fish oil nor
aspirin was effective in reducing the frequency and duration of CVC use, the frequency of late
dialysis suitability failure or the time to first successful cannulation. Similarly, the time to first
AVF intervention, primary patency loss or AVF abandonment did not differ significantly
between treatment groups.
Fish oil had no effect on the primary composite outcome of AVF failure[12], defined as the
proportion of participants with AVF thrombosis, AVF abandonment and/or cannulation fail-
ure within 12 months of access creation. However, these secondary outcome analyses sug-
gested a significant treatment benefit of fish oil in reducing the rate of AVF interventions.
Similar findings were reported in arteriovenous grafts by Lok and colleagues[11], whereby fish
oil did not significantly reduce the proportion of AVG thrombosis or interventions to maintain
patency but did lead to a clinically meaningful reduction in rates of thrombosis and access
interventions. These observations suggest that count outcomes (i.e. rates) are more sensitive to
the detection of changes by interventions compared to binary outcomes (i.e. proportions). In
addition, a reduction in intervention rates but not in either the proportion of AVFs requiring
intervention or time to first intervention suggests that fish oil may be beneficial in reducing
recurrent interventions. Interventions, such as angioplasties, thrombectomies and revisions,
can increase the risk of recurrent thrombosis and stenosis due to disruption of the endothelial
layer and subsequent vasoconstrictive, pro-inflammatory and pro-coagulative responses[18].
The vasodilatory[19], anti-inflammatory[8,9], anti-aggregatory[6,7], and anti-proliferative
Fig 4. AVF intervention rates for fish oil versus placebo (A) and aspirin versus placebo (B). Overall interventions:
Surgical or radiological revision or dilatation of the AVF from or proximal to the anastomosis to the ipsilateral central vein,
dilation of central venous stenosis, ligation of tributaries, superficialisation of AVF, thrombolysis or thrombectomy,
ligation of fistula or salvage by distal reconstruction and interval ligation, others. Rescue interventions: Thrombolysis or
thrombectomy. Non-rescue interventions: Surgical or radiological revision or dilatation of the AVF from or proximal to
the anastomosis to the ipsilateral central vein, dilation of central venous stenosis, ligation of tributaries, superficialisation of
AVF, ligation of fistula or salvage by distal reconstruction and interval ligation. Regions included Australia and New
Zealand, Malaysia and the United Kingdom. Pre-specified baseline characteristics included planned AVF site (lower arm,
upper arm), diabetes mellitus, age group (quartiles), cardiovascular comorbidity, including any one or more of peripheral
vascular disease, ischaemic heart disease and cerebrovascular accidents, and renal replacement therapy at baseline (no
[pre-dialysis/transplant], yes [haemodialysis or peritoneal dialysis]). aAdjusted for differences in aspirin use (no aspirin,
randomized to aspirin, open-label aspirin).
https://doi.org/10.1371/journal.pone.0213274.g004
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effects[10] of fish oil may be beneficial in reducing this risk and hence the need for recurrent
interventions. Additional studies might further explore the potential benefit of fish oil supple-
mentation in secondary prevention of AVF interventions.
High-dose aspirin given as 1000 mg every other day has previously been shown to reduce
access thrombosis within the first 28 days of AVF creation[20]. To minimize the risk of bleed-
ing complications, a lower dose of aspirin (100 mg) was used in the FAVOURED trial. Low-
dose aspirin, while not associated with increased bleeding, did not reduce the frequency of
access thrombosis during the first 12 months of AVF creation as previously shown[12]. How-
ever, similar to fish oil there may be a potential role for low-dose aspirin to reduce intervention
rates for access thrombosis that warrants confirmation in larger trials.
Vascular access function is the most frequently reported vascular access outcome but is
very heterogeneous with almost 900 measures used to assess the usability and function of an
access[5]. These additional analyses from the FAVOURED study provide novel information
across a broad range of outcomes related to dysfunction of a newly created AVF including
patency loss, need for interventions, CVC exposure, cannulation failure and access abandon-
ment. Patients, caregivers and health professionals all consider the need for access interven-
tions the most important clinical outcome measure of the function of a vascular access[21].
From a patient’s perspective, the number of interventions and intervention-free time have a
dramatic impact on their quality of life and well-being because access procedures are burden-
some and time-consuming[21,22]. Financial costs associated with AVF procedures account
for more than half of the expenditure in the first year of AVF creation even without accounting
for secondary expenditure for prolonged hospitalisation or procedure-related complications
[3]. It is possible that inexpensive interventions including fish oil or low-dose aspirin to reduce
AVF-related procedures may be cost-saving and have a positive impact on the patients’ well-
being and warrants evaluation in future studies.
More than a third of participants were unable to use their study AVF for dialysis by 6
months after access creation. This is comparable to the national average of AVF use of 36% in
prevalent HD patients of the United States (U.S.)[23] and 39% reported in the U.S. Haemodia-
lysis Fistula Maturation study[24]. Of note, in the North American study investigating the
effect of clopidogrel on early fistula thrombosis and dialysis suitability failure[25], 61% of par-
ticipants were unable to use their fistula reliably for HD. The higher prevalence of cardiovascu-
lar disease (25%) and participants of black ethnicity (50%), and the use of a more stringent
definition that included a minimum machine blood flow rate of 300 mL/min may have con-
tributed to the higher frequency of dialysis suitability failure in the clopidogrel trial. Neither
fish oil nor aspirin in our study, or clopidogrel in the North American study[25], were effective
in improving dialysis suitability despite reducing rescue intervention rates and early thrombo-
sis, respectively. Dialysis suitability, while a clinically meaningful and relevant outcome, is
multifaceted and not only the result of a complex fistula maturation process but also that of a
multidisciplinary team effort comprising different surgical techniques, variations in fistula
care and cannulation skills. A single treatment agent may therefore not be sufficient to alter
such a complex outcome. Multipronged health service intervention studies that include phar-
macological, patient- (e.g. vein preservation, AVF care) and clinician-directed (e.g. surgical
technique, cannulation skills, access surveillance) interventions to improve AVF outcomes
may be required and warrant further exploration.
Fig 5. Time to primary AVF patency loss for fish oil versus placebo (A) and aspirin versus placebo (B). Kaplan-Meier curve
for active therapy (solid line with 95% confidence interval in light gray) and matching placebo (dashed line with 95% confidence
interval in dark gray).
https://doi.org/10.1371/journal.pone.0213274.g005
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Fig 6. Time to AVF abandonment for fish oil versus placebo (A) and aspirin versus placebo (B). Kaplan-Meier curve for
active therapy (solid line with 95% confidence interval in light gray) and matching placebo (dashed line with 95% confidence
interval in dark gray).
https://doi.org/10.1371/journal.pone.0213274.g006
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Our study addresses multiple clinically meaningful and relevant outcomes to assess AVF
function, particularly the need for intervention. However, the study has some limitations that
should be considered. Considering the 95% CI, the treatment benefits of fish oil in reducing
intervention rates might have been as low as 16% or as large as 76% and a reduction in late
dialysis suitability failure by up to 21% cannot be excluded. For enhanced precision in treat-
ment estimates, a larger study would be required. It is possible that fish oil supplementation or
aspirin use beyond the first three months may have had prolonged benefits in reducing the
need for access interventions or CVCs. Three months of therapy were selected because early
thrombosis and physiologic maturation (i.e. AVF flow and vein diameter) typically occur
within the first few weeks of AVF creation[26,27]. However, there is significant variability in
the time to successful clinical maturation. Studies have shown a range in median time from
AVF creation to cannulation of 25 days in Japan to 98 days in the U.S. based on the Dialysis
Outcomes and Practice Patterns Study[28]. These observations reflect differences in case-mix,
care processes, AVF complications (e.g. infiltrations), and AVF procedures[24] and are not
expected to be influenced by fish oil or aspirin use.
Conclusions
Secondary outcomes of the FAVOURED study suggest that three months of fish oil supple-
mentation or low-dose aspirin use may be beneficial in reducing intervention rates for acute
thrombosis in newly formed AVF. However, neither fish oil nor aspirin was effective in reduc-
ing CVC exposure, decreasing dialysis suitability failure or prolonging the time to primary
patency loss, access abandonment, first successful cannulation or first access intervention.
Given the importance of access interventions to patients and health professionals and associ-
ated costs, we consider further studies to explore benefits of ongoing fish oil supplementation
or low-dose aspirin use, particularly for secondary prevention of access interventions to be
warranted.
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